Soluble urokinase-type plasminogen activator receptor improves early risk stratification in cardiogenic shock

Autoři	HONGISTO Mari LASSUS Johan TARVASMAKI Tuukka SANS-ROSELLO Jordi TOLPPANEN Heli KATAJA Anu JANTTI Toni SABELL Tuija BANASZEWSKI Marek SILVA-CARDOSO Jose PARISSIS John JURKKO Raija ŠPINAR Jindřich CASTREN Maaret MEBAZAA Alexandre MASIP Josep HARJOLA Veli Pekka NETWORK CardShock Study Investigators And The Great
Rok publikování	2022
Druh	Článek v odborném periodiku
Časopis / Zdroj	EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
www	https://academic.oup.com/ehjacc/article/11/10/731/6660742?login=true
Doi	http://dx.doi.org/10.1093/ehjacc/zuac096
Klíčová slova	Cardiogenic shock; suPAR; Risk stratification; Biomarker
Popis	Aims Soluble urokinase-type plasminogen activator receptor (suPAR) is a biomarker reflecting the level of immune activation. It has been shown to have prognostic value in acute coronary syndrome and heart failure as well as in critical illness. Considering the complex pathophysiology of cardiogenic shock (CS), we hypothesized suPAR might have prognostic properties in CS as well. The aim of this study was to assess the kinetics and prognostic utility of suPAR in CS. Methods and results SuPAR levels were determined in serial plasma samples (0-96 h) from 161 CS patients in the prospective, observational, multicentre CardShock study. Kinetics of suPAR, its association with 90-day mortality, and additional value in risk-stratification were investigated. The median suPAR-level at baseline was 4.4 [interquartile range (IQR) 3.2-6.6)] ng/mL. SuPAR levels above median were associated with underlying comorbidities, biomarkers reflecting renal and cardiac dysfunction, and higher 90-day mortality (49% vs. 31%; P = 0.02). Serial measurements showed that survivors had significantly lower suPAR levels at all time points compared with nonsurvivors. For risk stratification, suPAR at 12 h (suPAR(12h)) with a cut-off of 4.4 ng/mL was strongly associated with mortality independently of established risk factors in CS: OR 5.6 (95% CI 2.0-15.5); P = 0.001) for death by 90 days. Adding suPAR(12h) > 4.4 ng/mL to the CardShock risk score improved discrimination identifying high-risk patients originally categorized in the intermediate-risk category. Conclusion SuPAR associates with mortality and improves risk stratification independently of other previously known risk factors in CS patients.